These Stocks Are Today's Movers: Wells Fargo, JPMorgan, BlackRock, American, Credo, CarMax, J&J, and More -- Barrons.com

Dow Jones04-14

By Mackenzie Tatananni and George Glover

Stock futures were mostly higher Tuesday as investors gathered hope for a peace deal between the U.S. and Iran and big banks ushered in the earnings season.

These stocks were poised to make moves:

Wells Fargo fell 2%. First-quarter net interest income came to $12.1 billion, missing analysts' forecasts for $12.3 billion and marking a 2% decline from the previous quarter.

JPMorgan Chase slipped 0.8%. The bank's first-quarter profit rose 13% to $16.5 billion, or $5.94 on a per-share basis, better than Wall Street's calls for $5.45. Revenue of $49.8 billion also topped estimates.

BlackRock gained 2.4%. The world's largest asset manager reported $2.2 billion in net income, marking a 46% jump from the same period last year. A record first quarter for BlackRock's iShares exchange-traded fund business contributed to $130 billion in net inflows.

Bloom Energy surged 15% on the heels of a deal announcement with Oracle to support the buildout of the latter's artificial-intelligence and cloud computing infrastructure. Oracle stock rose 3.6% and looked set to add to its gains from the previous session, where it closed up 13%.

CarMax tumbled 6.8%. The used-car dealer posted another year-over-year drop in quarterly earnings and revenue. CarMax recorded a $141.3 million goodwill impairment charge during the fiscal fourth quarter, driven by its falling stock price and weak financial performance.

Novo Nordisk gained 3.1% in the U.S. after the Danish drugmaker unveiled a partnership with OpenAI. Novo said it plans to use AI in drug discovery and supply chain improvements, and is targeting full integration by the end of the year.

Johnson & Johnson was down 1.5% even after first-quarter earnings and sales beat expectations. While sales of Stelara, J&J's former blockbuster, continued to decline, multiple myeloma treatment Darzalex and anti-inflammatory medicine Tremfya drove strength in the company's Innovative Medicines portfolio.

Credo Technology Group jumped 16% after the electrical cable provider said it would buy chip maker DustPhotonics as it bids to become the dominant player in AI connectivity.

Intel advanced 0.9%, putting the chip maker on course to extend its winning streak to 10 sessions. Shares have jumped 58% over the past nine trading days, rallying thanks to collaborations with Tesla and Alphabet's Google, and Intel buying back full control of its chip factory in Ireland.

American Airlines and United Airlines added 7.8% and 2.9%, respectively, after Bloomberg reported that United CEO Scott Kirby had pitched a potential combination between the two carriers. The outlet cited people familiar with the matter.

Globalstar was up 0.9% following a report that Amazon was in talks to acquire the satellite operator, with a deal announced as soon as Tuesday. Globalstar and Amazon didn't immediately respond to requests for comment.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com and George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

April 14, 2026 07:45 ET (11:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment